Reprogramming MFALCs immune cells: an innovative therapeutic strategy for chronic obstructive pulmonary disease (COPD)

Research Project

Project/Area Number	25K11423
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 53030:Respiratory medicine-related
Research Institution	Hokkaido University
Principal Investigator	エレワヤセル北海道大学, 獣医学研究院, 助教 (30782221)
Co-Investigator(Kenkyū-buntansha)	Abdrabou Shimaa 北海道大学, 医学研究院, 助教 (30970587) マハモドヨニス北海道大学, 薬学研究院, 特任助教 (60985109)
Project Period (FY)	2025-04-01 – 2028-03-31
Project Status	Granted (Fiscal Year 2025)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2027: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2026: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	COPD / Lung cancer (LC) / MFALCs / immunotherapy
Outline of Research at the Start	Impact of mice strain differences and epigenetics on MFALCs development and chronic obstructive pulmonary diseases(COPD) pathogenesis. Impact of nanoparticle preparation of immunotherapy on COPD resolution and MFALCs. Impact of nanoparticle preparation of natural product extract (NPE) on COPD resolution.